Advertisement

Image-Guided Percutaneous Bleomycin and Bevacizumab Sclerotherapy of Orbital Lymphatic Malformations in Children

  • Omar AbdelazizEmail author
  • Farouk Hassan
  • Kareem Elessawy
  • Sally Emad-Eldin
  • Rania El Essawy
Clinical Investigation Non-Vascular Interventions
Part of the following topical collections:
  1. Non-Vascular Interventions

Abstract

Purpose

To evaluate the effectiveness and safety of image-guided percutaneous sclerotherapy using bleomycin for macrocystic and bevacizumab (Avastin™) for microcystic orbital lymphatic malformations in children.

Materials and Methods

Between October 2015 and July 2018, we prospectively evaluated 10 pediatric patients who presented clinically and radiologically with lymphatic malformations and were treated with percutaneous sclerotherapy. Patients with venous malformations were excluded. Eight females and two males with ages ranging from 3 to 17 years (mean: 8.8, SD: 4.9) were included. Guided with ultrasound and fluoroscopy, macrocysts were treated with bleomycin instillation. For microcystic components in three patients, bevacizumab was injected intralesional. All patients underwent ultrasound and non-contrast MRI to evaluate response to treatment after 6 weeks.

Results

The malformations were macrocystic in seven patients and complex (macro/microcystic) in three. Twenty sclerotherapy sessions were performed, (range: 1–3 sessions, mean: 2, SD: 0.8). Clinically, there was a significant reduction in the proptosis after treatment (P = 0.007) and dystopia (P = 0.018). The local radiological response showed a reduction in the maximum lesions diameters and volumes after treatment (P = 0.005 and 0.005, respectively). Two of the three patients treated with bevacizumab showed a reduction in the lesions volumes by 90.4% and 63.4%, respectively, whereas one patient did not show volume reduction. Transient periorbital edema and ecchymosis occurred following the procedure with no major complications encountered. Follow-up ranged from 9–33 months, mean: 20.3, SD: 7.4.

Conclusion

Bleomycin sclerotherapy is a safe and effective treatment for orbital macrocystic lymphatic malformations. Further use of bevacizumab for microcystic lesions in a larger series is required to outline its efficacy and safety.

Keywords

Orbital vascular malformations Sclerotherapy Bleomycin Bevacizumab 

Notes

Acknowledgements

The authors wish to acknowledge the help provided by Dr. Alex M Barnacle, Consultant Interventional Radiologist, Great Ormond Street Hospital for Children, NHS, London, UK. We would like to thank her for the expert advice and encouragement throughout this work. Her willingness to give her time so generously in editing the manuscript has been very much appreciated.

Compliance with Ethical Standards

Conflicts of interest

On behalf of all authors, the corresponding author states that there are no conflicts of interest.

Ethical Standards

All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all legal guardians of the children.

References

  1. 1.
    Katz SE, Rootman J, Vangveeravong S, Graeb D. Combined venous lymphatic malformations of the orbit (so-called lymphangiomas): association with noncontiguous intracranial vascular anomalies. Ophthalmology. 1998;105(1):176–84.CrossRefGoogle Scholar
  2. 2.
    Greene AK, Burrows PE, Smith L, et al. Periorbital lymphatic malformation: clinical course and management in 42 patients. Plast Reconstr Surg. 2005;115:22–30.CrossRefGoogle Scholar
  3. 3.
    Mulligan PR, Prajapati HJS, Martin LG, Patel TH. Vascular anomalies: classification, imaging characteristics and implications for interventional radiology treatment approaches. Br J Radiol. 2014;87:1035.CrossRefGoogle Scholar
  4. 4.
    Chung EM, Smirniotopoulos JG, Specht CS, Schroeder JW, Cube R. From the archives of the AFIP: pediatric orbit tumors and tumorlike lesions: non-osseous lesions of the extra ocular orbit. Radiographics. 2007;27:1777–99.CrossRefGoogle Scholar
  5. 5.
    Rootman J, Heran MKS, Graeb DA. Vascular malformations of the orbit: classification and the role of imaging in diagnosis and treatment strategies. Ophthal Plast Reconstr Surg. 2014;30:91–104.CrossRefGoogle Scholar
  6. 6.
    Tunc M, Sadri E, Char DH. Orbital lymphangiomas: an analysis of 26 patients. Br J Ophthalmol. 1999;83:76–80.CrossRefGoogle Scholar
  7. 7.
    Gündüz K, Demirel S, Yagmurlu B, Erden E. Correlation of surgical outcome with neuroimaging findings in periocular lymphangiomas. Ophthalmology (Internet). 2006;113(7):1231–8.Google Scholar
  8. 8.
    Nassiri N, Rootman J, Rootman DB, Goldberg RA. Orbital lymphaticovenous malformations: current and future treatments. Surv Ophthalmol. 2015;60:383–405.CrossRefGoogle Scholar
  9. 9.
    Güneyli S, Ceylan N, Bayraktaroğlu S, Acar T, Savaş R. Imaging findings of vascular lesions in the head and neck. Diagn Interv Radiol. 2014;20(5):432–7.CrossRefGoogle Scholar
  10. 10.
    Harris GJ, Sakol PJ, Bonavolonta G, et al. An analysis of thirty cases of orbital lymphangiomas: pathophysiologic considerations and management recommendations. Ophthalmology. 1990;97:1583–92.CrossRefGoogle Scholar
  11. 11.
    Barnacle AM, Theodorou M, Maling SJ, Abou-Rayyah Y. Sclerotherapy treatment of orbital lymphatic malformations: a large single-center experience. Br J Ophthalmol. 2016;100(2):204–8.CrossRefGoogle Scholar
  12. 12.
    Wojno TH. Sotradecol (sodium tetradecyl sulfate) injection of orbital lymphangioma. Ophthal Plast Reconstr Surg. 1999;15:432–7.CrossRefGoogle Scholar
  13. 13.
    Svendsen PA, Wikholm G, Rodriguez M, et al. Direct puncture and sclerotherapy with Sotradecol. Orbital lymphatic malformations. Interv Neuroradiol. 2001;30:193–9.CrossRefGoogle Scholar
  14. 14.
    Poonyathalang A, Preechawat P, Jiarakongmun P, et al. Sclerosing therapy for orbital lymphangioma using sodium tetradecyl sulfate. Jpn J Ophthalmol. 2008;52:298–304.CrossRefGoogle Scholar
  15. 15.
    Hill RH, Shiels WE, Foster JA, et al. Percutaneous drainage and ablation as first-line therapy for macrocystic and microcystic orbital lymphatic malformations. Ophthal Plast Recontr Surg. 2012;28:119–25.CrossRefGoogle Scholar
  16. 16.
    Chiramel GK, Keshava SN, Moses V, Mammen S, David S, Sen S. Percutaneous sclerotherapy of congenital slow-flow vascular malformations of the orbit. Cardiovasc Intervent Radiol. 2015;38:270–9.CrossRefGoogle Scholar
  17. 17.
    Patel KC, Kalantzis G, El-Hindy N, Chang BY. Sclerotherapy for orbital lymphangioma—case series and literature review. In Vivo. 2017;31(2):263–6.CrossRefGoogle Scholar
  18. 18.
    Shen CY, Wu MC, Tyan YS, Ou CH, Chen TY, Wong HF. Preliminary experience of percutaneous intralesional bleomycin injection for the treatment of orbital lymphatic-venous malformation refractory to surgery. Clin Radiol. 2012;67:182–4.CrossRefGoogle Scholar
  19. 19.
    Gooding C, Meyer D. Intralesional bleomycin: a potential treatment for refractory orbital lymphangiomas. Ophthal Plast Reconstr Surg. 2014;30:65–7.Google Scholar
  20. 20.
    Paramasivam S, Fay A, Fifi J, Berenstein A. O-015 Image guided bleomycin sclerotherapy for orbital lymphatic malformation. J Neuro Intervent Surg. 2014;6:A8–9.Google Scholar
  21. 21.
    Harmoush S, Chinnardurai P, El Salek K, et al. Multimodality image-guided sclerotherapy of low-flow orbital vascular malformations: report of single-center experience. J Vasc Interv Radiol. 2016;27(7):987–95.CrossRefGoogle Scholar
  22. 22.
    Raichura N, Alam S, Noronha V, Mukherjee B. A prospective study of the role of intralesional bleomycin in orbital lymphangioma. J AAPOS. 2017;21:146–51.CrossRefGoogle Scholar
  23. 23.
    Hanif AM, Saunders JA, Hawkins CM, Wojno TH, Kim HJ. Use of percutaneous bleomycin sclerotherapy for orbital lymphatic malformations. Orbit. 2018;14:1–7.CrossRefGoogle Scholar
  24. 24.
    Suzuki Y, Obana A, Gohto Y, et al. Management of orbital lymphangioma using intralesional injection of OK-432. Br J Ophthalmol. 2000;84:614–7.CrossRefGoogle Scholar
  25. 25.
    Woo YJ, Kim CY, Sgrignoli B, Yoon JS. Orbital lymphangioma: characteristics and treatment outcomes of 12 cases. Korean J Ophthalmol. 2017;31(3):194–201.CrossRefGoogle Scholar
  26. 26.
    Yue H, Qian J, Elner VM, et al. Treatment of orbital vascular malformations with intralesional injection of pingyangmycin. Br J Ophthalmol. 2013;97:739–45.CrossRefGoogle Scholar
  27. 27.
    Schwarcz RM, Ben Simon GJ, Cook T, et al. Sclerosing therapy as first-line treatment for low flow vascular lesions of the orbit. Am J Ophthalmol. 2006;141:333–9.CrossRefGoogle Scholar
  28. 28.
    Thomas DM, Wieck MM, Grant CN, et al. Doxycycline sclerotherapy is superior in the treatment of pediatric lymphatic malformations. J Vasc Interv Radiol. 2016;27(12):1846–56.CrossRefGoogle Scholar
  29. 29.
    Orford J, Barker A, Thonell S, King P, Murphy J. Bleomycin therapy for cystic hygroma. J Pediatr Surg. 1995;30:1282–7.CrossRefGoogle Scholar
  30. 30.
    Baskin D, Tander B, Bankaoglu M. Local bleomycin injection in the treatment of lymphangioma. Eur J Pediatr Surg. 2005;15:383–6.CrossRefGoogle Scholar
  31. 31.
    Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO. Intralesional bleomycin injection (IBI) treatment for haemangiomas and vascular malformations. Pediatr Surg Int. 2004;19:766–73.CrossRefGoogle Scholar
  32. 32.
    Horbach SE, Rigter IM, Smitt JH, et al. Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis. Plast Reconstr Surg. 2016;137:244–56.CrossRefGoogle Scholar
  33. 33.
    Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.CrossRefGoogle Scholar
  34. 34.
    Pasqualetti G, Danesi R, Del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics. 2007;8(1):49–66.CrossRefGoogle Scholar
  35. 35.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.CrossRefGoogle Scholar
  36. 36.
    Arevalo JF, Lasave AF, Wu L, Diaz-Llopis M, Gallego-Pinazo R, Alezzandrini AA, et al. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-American Collaborative Retina Study Group at 24 months. Retina. 2013;33(2):403–13.CrossRefGoogle Scholar
  37. 37.
    Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Cantón V, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months. Retina. 2010;30(7):1002–11.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018

Authors and Affiliations

  1. 1.Department of Diagnostic and Interventional RadiologyCairo University HospitalsCairoEgypt
  2. 2.Department of OphthalmologyCairo University HospitalsCairoEgypt

Personalised recommendations